What is the difference between MK-4 and MK-7 in terms of how long they stay in the body?

A direct nutritional-dose study did not calculate one-hour and 26-hour half-lives. It found that MK-7 peaked in serum at 6 hours and remained detectable for up to 48 hours after 420 mcg, while MK-4 was not detectable after the same microgram dose (PMID: 23140417). These findings should not be extrapolated to pharmacologic 45 mg MK-4 dosing or treated as proof of tissue accumulation.

Which form is better for bone health: MK-4 or MK-7?

There is no direct head-to-head fracture trial proving that one form is better. A three-year placebo-controlled study supports 180 mcg/day MK-7 for selected bone measures in healthy postmenopausal women (PMID: 23525894), while a 24-month open-label study supports pharmacologic 45 mg/day MK-4 in patients with osteoporosis (PMID: 10750566). The populations, doses, and designs are not equivalent.

Can I take vitamin K2 if I'm on warfarin or another blood thinner?

Vitamin K2 can antagonize warfarin's effect. Do not start, stop, or switch MK-4 or MK-7 without the anticoagulation clinician directing the plan and INR monitoring. This page does not recommend one form as safer during warfarin therapy. Other anticoagulants also warrant medication-specific clinical advice.

What dose of MK-7 is equivalent to the MK-4 doses used in clinical trials?

No validated dose conversion can make the MK-4 and MK-7 trial regimens equivalent. The cited MK-4 study used 45 mg/day, while the cited MK-7 study used 180 mcg/day in a different population and design. Comparing those doses by weight does not establish comparable biological or clinical effects.

Will my gut bacteria convert vitamin K1 (phylloquinone) to vitamin K2 if I don't supplement?

Human vitamin-K metabolism is more complex than a simple gut-bacteria conversion percentage. The previously cited source did not study vitamin K, so this page does not claim a quantified K1-to-MK-4 conversion rate. Dietary adequacy and any need for supplementation should be assessed in clinical context.

Is MK-7 or MK-4 better absorbed with food?

Vitamin K is fat-soluble, and the direct bioavailability study administered both forms with a standardized breakfast (PMID: 23140417). It did not test a 5–10 gram fat threshold or establish MK-7 superiority under malabsorption or fasting conditions. Follow product and clinician instructions.

Comparative Analysis

Vitamin K2 MK-4 (Menatetrenone) vs MK-7 (Menaquinone-7): Complete Comparison

Q: How long does it take to see benefits from vitamin K2 supplementation?

Benefits are not immediate. Gla protein carboxylation and bone turnover marker improvements typically emerge over 3–6 months of consistent supplementation, with more substantial effects visible at 12 months. Bone mineral density improvements (1–3% annually) require minimum 12-month supplementation to reliably detect. MK-7's consistent daily levels may produce detectable changes slightly faster than sporadic MK-4 dosing, though individual variability is significant.

Compare MK-4 and MK-7 serum availability, studied doses, bone-health evidence, and anticoagulant cautions without assuming dose equivalence.

Vitamin K2 MK-4 (menatetrenone)Moderate EvidencevsVitamin K2 MK-7 (menaquinone-7)Moderate Evidence

Supplements compared

Moderate

Evidence context

May 2026

Updated

Protocol

Dosing and safety

Supplements compared

Moderate

Evidence context

May 2026

Updated

Protocol

Dosing and safety

Evidence graded

Transparent methodology

Safety reviewed

Interactions and cautions

Cost compared

Value and serving cost

Updated regularly

New evidence tracked

Practical protocol

Dosing context included

Quick Answer

The Short Version

At nutritional doses, MK-7 remains detectable in serum longer than MK-4. However, MK-4 and MK-7 bone studies use very different doses, populations, and designs, so they are not directly dose-equivalent and neither form is universally superior. The choice depends on the clinical goal, diet, dose, and medication interactions.

Where to Buy

Want the checklist behind these comparisons?

Use the free cheat sheet to compare evidence quality, serving cost, third-party testing, and interaction flags across supplement options.

Get the checklist

This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

Head to Head

Key Differences

Factor	Vitamin K2 MK-4 (menatetrenone)	Vitamin K2 MK-7 (menaquinone-7)
Bioavailability & Absorption	In a direct nutritional-dose study, serum MK-4 was not detectable after a single 420 mcg dose or after 60 mcg daily for 7 days; this does not describe the pharmacokinetics of pharmacologic 45 mg MK-4 dosing (PMID: 23140417).	In the same small study, MK-7 reached its maximum serum level at 6 hours after a 420 mcg dose and remained detectable for up to 48 hours; 60 mcg daily for 7 days increased serum MK-7 (PMID: 23140417).
Half-Life & Duration	The direct nutritional-dose study did not calculate an MK-4 half-life; serum MK-4 was not detectable after the tested 420 mcg dose (PMID: 23140417).	The same study did not calculate a 26-hour half-life; MK-7 peaked at 6 hours and remained detectable for up to 48 hours after 420 mcg (PMID: 23140417).
Tissue Distribution & Accumulation	Tissue-specific clinical advantages cannot be inferred from the small serum bioavailability study; pharmacologic MK-4 has been evaluated separately in osteoporosis research.	Longer circulation provides a rationale for sustained extrahepatic vitamin-K availability, but serum detection should not be equated with proven preferential accumulation in every tissue (PMID: 23140417).
Dietary Sources & Endogenous Production	MK-4 occurs in some animal-derived and fermented foods and can also be formed in tissues from other vitamin-K forms. This page does not quantify human gut conversion because the previously cited PMID did not study vitamin K.	Produced by gram-positive bacteria in fermented foods (sauerkraut, cheese, natto); more bioavailable from dietary sources than MK-4; bacterial conversion to MK-7 is minimal.
Cost & Availability	Generally more expensive per dose ($0.50–$2.00 per 45 mg dose); less commonly formulated in single-dose supplements due to dosing frequency requirements.	More affordable ($0.10–$0.40 per 45 mcg dose); widely available in single daily-dose formulations, reducing cost-per-serving for long-term use.
Research Evidence for Bone Health	A 24-month randomized open-label study in 241 patients with osteoporosis found fewer clinical fractures and less lumbar bone-density decline with 45 mg/day MK-4 than no treatment, but the design was not blinded (PMID: 10750566).	A three-year placebo-controlled trial in 244 healthy postmenopausal women found 180 mcg/day MK-7 reduced age-related decline at some bone sites; extrapolation to other populations remains uncertain (PMID: 23525894).

Who Should Take What

Best For

Daily supplementation for bone health support

MK-7's once-daily dosing (45–180 mcg) is more convenient and consistent than MK-4's three-times-daily regimen (45 mg). Better compliance supports sustained Gla protein activation over time.

Vitamin K2 MK-7 (menaquinone-7)

Rapid tissue targeting for localized bone metabolism

Pharmacologic MK-4 has been studied in osteoporosis, but evidence does not establish rapid localized tissue targeting as a reason for short-term self-treatment.

Vitamin K2 MK-4 (menatetrenone)

Individuals with fat malabsorption disorders

Fat malabsorption can affect vitamin-K status and may require condition-specific testing and treatment. The available comparison evidence does not show that MK-7 reliably offsets malabsorption.

Vitamin K2 MK-7 (menaquinone-7)

Long-term vascular and systemic health support

MK-7's sustained serum availability provides a mechanistic rationale, but this comparison does not establish superior prevention or treatment of vascular calcification.

Vitamin K2 MK-7 (menaquinone-7)

Budget-conscious supplementation

MK-7 offers lower per-dose costs ($0.10–$0.40 vs $0.50–$2.00 for MK-4) and requires fewer daily capsules, reducing overall supplementation expenses significantly over 6–12 months.

Vitamin K2 MK-7 (menaquinone-7)

Patients on chronic anticoagulation therapy

Neither form should be started, stopped, or switched during vitamin-K-antagonist therapy without the anticoagulation clinician directing the change and INR monitoring.

Neither without clinician oversight

The Science

Evidence Snapshot

The strongest directly relevant studies answer different questions. Shiraki et al. (PMID: 10750566) enrolled 241 patients with osteoporosis in a 24-month randomized open-label study of 45 mg/day MK-4 versus no treatment. Clinical fractures were less frequent and lumbar bone-density decline was smaller in the MK-4 group, but the lack of blinding and untreated comparator limit certainty. Knapen et al. (PMID: 23525894) randomized 244 healthy postmenopausal women to 180 mcg/day MK-7 or placebo for three years. MK-7 improved vitamin-K status and reduced age-related decline in bone measures at the lumbar spine and femoral neck, but not total-hip bone mineral density. Results may not extrapolate to men, younger adults, or patients with osteoporosis. A nutritional-dose bioavailability study (PMID: 23140417) found much more sustained serum detection of MK-7 than MK-4, but it does not establish clinical dose equivalence, exact half-lives, or superiority for fractures. ### Angelique review update: MK-4 vs MK-7 nuance MK-7 circulates longer at nutritional doses, while MK-4 has also been studied at much higher pharmacologic doses. Microgram-for-microgram comparisons are therefore misleading. Natto is a rich dietary MK-7 source; people with soy allergy should verify product sources.

Safety

Safety & Interactions

The primary safety issue is interaction with vitamin-K antagonists such as warfarin or phenprocoumon. Either K2 form can change anticoagulant control, so patients must not start, stop, or switch supplements without their anticoagulation clinician directing the change and INR monitoring. The comparison evidence does not establish that MK-4 is a safer workaround. People who are pregnant, breastfeeding, have a clotting disorder, or take other anticoagulants should seek medication-specific clinical advice before supplementation. **Take with food as directed:** Vitamin K2 is fat-soluble. The direct bioavailability study administered both forms with a standardized breakfast but did not define an optimal fat threshold. **Bacterial / soy context:** MK-7 is often produced by bacterial fermentation and natto-derived products may involve soy. People with soy allergy should verify the source.

Standard safety disclaimers

Pregnancy and breastfeeding: Consult your healthcare provider before taking this supplement during pregnancy or while nursing. The safety of supplemental doses beyond dietary intake has not been established in pregnant or lactating women.
Blood thinners: If you take blood-thinning medications (e.g., warfarin, apixaban, rivaroxaban, clopidogrel, or high-dose aspirin), consult your healthcare provider BEFORE starting this supplement, as it may have additive antiplatelet or anticoagulant effects.
Kidney disease: If you have chronic kidney disease (CKD) or any significant kidney impairment, consult your healthcare provider before taking this supplement. Some supplements can accumulate to dangerous levels when kidney function is reduced.
Gout: Individuals with gout should consult their healthcare provider before starting this supplement. Certain supplements (e.g., collagen, fish oil, niacin) may affect uric acid levels or trigger flares in susceptible individuals.
Important: This supplement is not a replacement for prescription medications. It is supportive for individuals with low baseline status, not a treatment for diagnosed conditions (anxiety disorders, insomnia, hypertension, osteoporosis, etc.). Do not stop or reduce any prescription without consulting your doctor.

This content is for educational purposes only and is not medical advice. These statements have not been evaluated by the FDA. Always consult your healthcare provider before starting any supplement.

Common Questions

Frequently Asked Questions

Both MK-4 and MK-7 are well-tolerated at standard supplemental doses with side effects rare and comparable to placebo in clinical trials. Occasionally reported mild adverse effects include nausea, constipation, or gastric discomfort, though these are not dose-dependent and occur in <2% of users. No serious toxicity has been documented with either form at recommended doses. The primary safety concern is interaction with anticoagulant medications rather than direct toxicity.

Benefits are not immediate. Gla protein carboxylation and bone turnover marker improvements typically emerge over 3–6 months of consistent supplementation, with more substantial effects visible at 12 months. Bone mineral density improvements (1–3% annually) require minimum 12-month supplementation to reliably detect. MK-7's consistent daily levels may produce detectable changes slightly faster than sporadic MK-4 dosing, though individual variability is significant.

Related Insights

For bone density applications, our vitamin k2 for bone health page covers osteocalcin carboxylation mechanisms, the MK-7 vs MK-4 half-life advantage for sustained activity, and how K2 synergizes with D3 and calcium.

Arterial calcification is the other key K2 application — our vitamin k2 for cardiovascular health page reviews Matrix-Gla Protein activation data, the Rotterdam Study findings, and MK-7 dose ranges used in arterial stiffness trials.

Vitamin K2 MK-4 (Menatetrenone) vs MK-7 (Menaquinone-7): Complete Comparison

The Short Version

Recommended Products